Infectious Disease · Pediatrics · 1 h ago
Temocillin PK Model Estimates Target Attainment in Young Children With UTIs
A population pharmacokinetic study analyzed sparse blood samples from 30 hospitalized children aged 6–34 months receiving temocillin for urinary tract infection. Simulations estimated more than 90% target attainment against organisms with an MIC of 2 mg/L or lower using the studied regimen, but the authors describe the findings as exploratory.
- Thirty children aged 6–34 months were included.
- The studied dose was 25 mg/kg twice daily.
- Simulated target attainment exceeded 90% at MICs ≤2 mg/L.
- Sparse sampling limits precision and covariate assessment.
Temocillin is being considered as a carbapenem-sparing option for infections caused by Gram-negative bacteria, including many ESBL-producing Enterobacterales. This study used population pharmacokinetic modeling to characterize the drug in children aged 6–34 months hospitalized with urinary tract infections. The 30 children received 25 mg/kg twice daily; analysis included 30 unbound and 33 total plasma concentrations obtained through sparse sampling.
A one-compartment model with nonlinear protein binding was supported. Estimated clearance was 2.81 L/h and volume of distribution was 10.3 L; interindividual variability in clearance was 21.2%. Monte Carlo simulations predicted greater than 90% probability of attaining the target of free-drug concentrations above the MIC for 40% of the dosing interval against organisms with MICs of 2 mg/L or lower.
The findings provide preliminary pharmacokinetic data for this age group, but do not establish clinical efficacy or support a change in treatment practice. Sparse sampling limits precision, assessment of variability and covariate evaluation. Target attainment is a modeled pharmacodynamic outcome, and the authors present the results as an exploratory reference for dosing considerations.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
The Pediatric Infectious Disease Journal: Pharmacokinetic Modeling and Dosing Simulations of Temocillin in Children With Urinary Tract Infections ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.